Skip to main content
. 2013 Aug 23;6(5):1343–1345. doi: 10.3892/ol.2013.1544

Figure 2.

Figure 2

Image of the CTC-KRAS mutational status for patient CR6. The CD45+ cell fraction (mainly leukocytes) provides a positive signal for the control assay corresponding to KRAS exon-4. The CD45/CD326 cell fraction exhibits a positive signal of the control assay corresponding to KRAS exon-4. The CD45/CD326+ cell fraction exhibits a positive signal of the control assay corresponding to KRAS exon-4 and a signal for the KRAS-12Ala mutation. CTC, circulating tumour cell.